CDC NEWS


powered by Surfing Waves


Latest News


AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis


23 Mar 2021

79% vaccine efficacy at preventing symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalization Comparable efficacy result across ethnicity and age, with 80% efficacy in participants aged 65 years and over Favorable reactogenicity and overall safety profile


Experts Discuss COVID-19—Vaccine Questions, School Openings, and More


17 Mar 2021

JAMA Live Highlights features comments from livestream interviews by JAMA Network Editor in Chief Howard Bauchner, MD. His discussions with experts in clinical care, public health, and health policy focus on critical issues related to the COVID-19 pandemic. Comments have been edited for clarity.


CDC Interim Recommendations for Fully Vaccinated People


10 Mar 2021

On December 11, 2020, the US reached an extraordinary milestone in the efforts to end the COVID-19 pandemic: the Food and Drug Administration authorized emergency use of the first COVID-19 vaccine, manufactured by Pfizer-BioNTech. Since then, 2 additional COVID-19 vaccines, Moderna and Janssen (Johnson & Johnson), have received Emergency Use Authorization in the US and, as of March 8, 2021, more than 31 million people, or 9.4% of the total population, have completed a vaccination series.


Approaches for Optimal Use of Different COVID-19 Vaccines Issues of Viral Variants and Vaccine Efficacy


04 Mar 2021

The efforts of the Biden administration to accelerate rollout of COVID-19 vaccines are enabling more adults in the US to be vaccinated each week. As of February 28, 2021, an estimated more than 48 million people have received at least 1 vaccine dose.


How the Johnson & Johnson Vaccine Works


28 Feb 2021

Johnson & Johnson is testing a coronavirus vaccine known as JNJ-78436735 or Ad26.COV2.S. Clinical trials showed that a single dose of the vaccine had an efficacy rate of up to 72 percent. The vaccine has been authorized for emergency use in the United States and Bahrain.




Articles


Study Suggests Lasting Immunity After COVID-19, With a Big Boost From Vaccination


14 Jul 2021

After an infection with SARS-CoV-2, most people—even those with mild infections—appear to have some protection against the virus for at least a year, a recent follow-up study of recovered patients published in Nature suggests. What’s more, this and other research demonstrates that vaccinating these individuals substantially enhances their immune response and confers strong resistance against variants of concern, including the B.1.617.2 (delta) variant.




Return to Play After COVID-19 Infection in Children


28 Jun 2021

As the pandemic continues, children may experience long-term effects from COVID-19 infections. Because children may become “long haulers” or develop multisystem inflammatory syndrome in children (MIS-C), close monitoring after a COVID-19 diagnosis is important. In addition, children who are athletes require a separate return-to-play evaluation before they return to competitive sports or physical activities.




Association of Mask Mandates and COVID-19 Case Rates, Hospitalizations, and Deaths in Kansas


23 Jun 2021

This study examined the association between mask mandates in Kansas counties and COVID-19 cases, hospitalizations, and deaths. The Kansas executive order that took effect on July 3 was adopted by only 15 counties, and 68 counties did not have a mandate through October. A second mask mandate order took effect on November 25, and 40 additional counties adopted it.




COVID-19 Vaccination of Health Care Personnel as a Condition of Employment A Logical Addition to Institutional Safety Programs


08 Jun 2021

The consequences of the SARS-CoV-2 pandemic have been far-reaching, particularly among health care personnel (HCP) and within health care settings. HCP have been directly affected, sustaining occupationally acquired COVID-19 infections, and indirectly through a substantial alteration in health care delivery. With the advent of highly effective and safe SARS-CoV-2 vaccines, case rates and hospitalization rates are declining, and the promise of a return to some semblance of pre–COVID-19 health care is growing. Recently, several medical centers have announced a requirement for SARS-CoV-2 vaccination of all HCP (allowing for medical and religious exemptions), and the impending licensure of the mRNA SARS-CoV-2 vaccines (following the previous Emergency Use Authorization [EUA]) will move many other centers to consider a similar policy. A recent outbreak in a skilled nursing facility attributed to an unvaccinated HCP member clearly illustrates the risk unvaccinated HCP can pose to their patients and other HCP.1




We are scheduling training with them this week on how to generate the report.


07 Jun 2021

The Centers for Disease Control and Prevention (CDC) recently issued guidance that fully vaccinated individuals can safely remove masks and end social distancing in most indoor settings.1 Educational facilities and businesses are faced with whether and how to differentiate between vaccinated and unvaccinated individuals, including requiring proof of vaccination. Mandatory vaccination has historically served as a tool to reach and sustain high immunization coverage and to prevent transmission in K-12 schools, colleges/universities, and health care facilities. Vaccine mandates could extend to workers and customers in businesses to ensure safer environments. This Viewpoint examines the epidemiologic, public health, and legal considerations for mandatory SARS-CoV-2 vaccinations in each setting.




Enroll for Free